

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

RECEIVED
OFFICE OF THE SENATE
SECRETARY
02 AUG 14 PM 1:59

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Pfizer, Inc.			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 325 7th Street, N.W. Suite 1200 City Washington State/Zip (or Country) DC 20004			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Justin McCarthy	Telephone 202-783-7070	E-mail (optional) justin.j.mccarthy@pfizer.com	5. Senate ID # 31326-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 31354000

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) **OR** Year End (July 1-Dec)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobbyi

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$1,900,000.00</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033 of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature _____

J. McCarthy

Date 8/15/2002

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code AGR (one per page)

16. Specific Lobbying issues
HR 5263, Agriculture Appropriations, pharmaceutical counterfeiting, importation
S 2801, Agriculture Appropriations, pharmaceutical counterfeiting, importation

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
LaMarca, Louis A.	
McCarthy, Justin	
Mullen, Heather M.	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/15/2002

Registrant Name: Pfizer, Inc.Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

HR 5263, Agriculture Appropriations, pharmaceutical counterfeiting, importation
S 2778, Commerce, State, Justice Appropriations, intellectual property protection
S 2801, Agriculture Appropriations, pharmaceutical counterfeiting, importation

17. House(s) of Congress and Federal agencies contacted

 Check if None

House of Representatives
Senate


18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	
Mullen, Heather M.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

 Check if None

Signature


Date 8/15/2002

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

- HR 1862 , The Greater Access to Affordable Pharmaceuticals Act of 2001, patents**
- HR 2887, The Better Pharmaceuticals for Children Act, pediatric pharmaceutical patents**
- S 2244, The Prescription Drug Price Parity for Americans Act , pharmaceutical counterfeiting**
- S 812, The Greater Access to Affordable Pharmaceuticals Act of 2001, patent issues**

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	
Mullen, Heather M.	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/15/2002

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CSP (one per page)


16. Specific Lobbying issues
S 2244, The Prescription Drug Price Parity for Americans Act, pharmaceutical counterfeiting, importation
S 2486, The Fair Advertising and Increased Research Act, advertising
Prescription and over the counter pharmaceuticals (no bills)

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
LaMarca, Louis A.	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/15/2002

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

- HR 1624, Consumer Access to Prescription Drugs Improvement Act, access to pharmaceuticals
- HR 2563, Bipartisan Patient Protection Act, liability issues
- HR 2887, The Better Pharmaceuticals for Children Act, Pediatric pharmaceuticals
- HR 3448, Prescription Drug User Fee Act Reauthorization of 2002, FDA user fees
- HR 3804, Preservation of Antibiotics for Human Treatment Act, pharmaceutical issues
- HR 4730, The Pediatric Drug Labeling Act, pediatric pharmaceuticals
- HR 4954, Medicare Modernization and Prescription Drug Act of 2002, Medicare reform and prescription dr
- S 10, Medicare Prescription Drug Coverage Act of 2001, Medicare reform
- S 2394, The Pediatric Drug Labeling Act, pediatric pharmaceuticals
- S 2536, State Medicaid Flexibility Act, medicaid and pharmaceutical coverage


17. House(s) of Congress and Federal agencies contacted Check if None

- Department of Health & Human Services
- Executive Office of the President
- Food & Drug Administration
- House of Representatives
- Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	
Mullen, Heather M.	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/15/2002

Registrant Name: **Pfizer, Inc.**Client Name: **Pfizer Inc**

Item	Description	Data
16	Lobbying Issues	S 357, Medicare Preservation and Improvement Act of 2001, Medicare reform
16	Lobbying Issues	S 358, Medicare Prescription Drug and Modernization Act of 2001, Medicare reform and prescription drug benefit
16	Lobbying Issues	S 913, Consumer Access to Prescription Drugs Improvement Act, access to pharmaceuticals
16	Lobbying Issues	President Bush's Immediate Helping Hand Proposal (no bills) (drug benefit)

Registrant Name: Pfizer, Inc.Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

HR 4954, Medicare Modernization and Prescription Drug Act of 2002, Medicare reform**S 10, Medicare Prescription Drug Coverage Act of 2001, Prescription drug benefit****S 357, Medicare Preservation and Improvement Act of 2001, Medicare reform****S 358, Medicare Prescription Drug and Modernization Act of 2001, Medicare reform****President Bush's Immediate Helping Hand Proposal (no bills) (drug benefit)**

17. House(s) of Congress and Federal agencies contacted

 Check if None**House of Representatives****Senate**


18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	
Mullen, Heather M.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

 Check if None

Signature


Date 8/15/2002

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code SCI (one per page)

16. Specific Lobbying issues

HR 3058, The Puppy Protection Act of 2001, animals in research

HR 3448, The Public Health Security and Bioterrorism Response Act of 2001, pharmaceutical supply and dist

S 1478, The Puppy Protection Act of 2001, animals in research

S 1765, The Bioterrorism Preparedness Act, pharmaceutical supply and distribution


17. House(s) of Congress and Federal agencies contacted Check if None

Department of Commerce
Department of Health & Human Services
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
LaMarca, Louis A.	
Mullen, Heather M.	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/15/2002

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues
no bills, , International repatriation tax
S 2486, The Fair Advertising and Increased Research Act, tax deductions

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/15/2002

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues

- HR 3005, The Trade Promotion Authority Act of 2001, intellectual property protection
- HR 3009 , The Trade Act of 2002, intellectual property protection
- S. 525, Andean Trade Preference Expansion Act of 2001, intellectual property protection
- International intellectual property protection (no bills)
- International pharmaceutical market access (no bills)
- WTO accession and implmentation issues (no bills)

17. House(s) of Congress and Federal agencies contacted Check if None

- Department of Commerce
- Department of State
- Executive Office of the President
- House of Representatives
- Office of U.S. Trade Representative
- Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/15/2002

